Selexis SA to Partner at BIO Asia 2012

Share Article

Selexis SA announced today representatives from the Company will be taking part in pre-scheduled partnering meetings at the 9th Annual BIO Asia International Conference being held January 31 – February 1, 2012 in Osaka, Japan.

News Image
Next to the United States, Japan has the largest number of biotechnology companies. BIO Asia is an ideal conference for us to highlight our innovations and our applications of the SUREtechnology Platform™ which can support Japan’s drug discovery efforts.

Selexis SA announced today representatives from the Company will be taking part in pre-scheduled partnering meetings at the 9th Annual BIO Asia International Conference being held January 31 – February 1, 2012 in Osaka, Japan.

“With a biotechnology market of 1.76 trillion yen (22.6 billion U.S. dollars), Japan represents a significant opportunity for Selexis,” said Igor Fisch, Ph.D, Selexis CEO. “Next to the United States, Japan has the largest number of biotechnology companies. BIO Asia is an ideal conference for us to highlight our innovations and our applications of the SUREtechnology Platform™ which can support Japan’s drug discovery efforts.”

Companies or individuals attending BIO Asia can schedule meetings with Selexis (registration required) by visiting: http://oneononepartnering.bio.org/bioasia2012/

Selexis Partnering Schedule:

Tuesday, January 31, 2012     8:00 AM – 6:00 PM
Wednesday, February 1, 2012    7:00 AM – 6:00 PM

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information:

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert Meister
Selexis SA
(602) 953-1716
Email >
Visit website